A Randomized, Controlled, Open-Label, Multicenter Phase ??? Clinical Study to Evaluate the Efficacy and Safety of SYS6010 Versus Investigator's Choice Chemotherapy in Patients With Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma Who Have Failed at Least One Line of Systemic Therapy.
Latest Information Update: 02 Mar 2026
At a glance
- Drugs CPO 301 (Primary) ; Docetaxel; Irinotecan; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors CSPC Megalith Biopharmaceutical
Most Recent Events
- 02 Mar 2026 New trial record